The spatial genomics and transcriptomics market is projected to reach $6.5 billion by 2036 from an estimated $0.73 billion in 2026, at a CAGR of 24.4% from 2026 to 2036. The market was valued at $0.66 billion in 2025. The growth of this market is primarily fueled by rising applications in drug discovery and cancer research, advancements in next generation sequencing and biomarker detection, and increasing investment and consolidation activity among market participants. Additionally, rising adoption of personalized medicines and FFPE-compatible workflows, and the expansion of contract research and outsourced spatial services are expected to create substantial growth opportunities for market participants.
The key players operating in the spatial genomics and transcriptomics market are 10x Genomics, Inc. (U.S.), Bruker Corporation (U.S.), Quanterix Corporation (U.S.), Illumina, Inc. (U.S.), Vizgen, Inc. (U.S.), Singular Genomics, Inc. (U.S.), Takara Bio Inc. (Japan), Oxford Nanopore Technologies Plc (U.K.), Revvity, Inc. (U.S.), Resolve Biosciences GmbH (Germany), S2 Genomics, Inc. (U.S.), Cantata Bio (U.S.), and BioSpyder Technologies, Inc. (U.S.).
The spatial genomics and transcriptomics market study presents historical market data value (2024 and 2025), estimated current data (2026), and forecasts for 2036. This market is segmented by offering, type, technology, application, end user, and geography.
Among all the offerings, the consumables segment is expected to account for the largest share of the spatial genomics and transcriptomics market in 2026. The dominant position of this segment is primarily attributed to consumables being proprietary to each platform, with consumption following the utilization of instruments already installed. The software & services segment is projected to register the highest growth, reflecting the analytical capability required to convert spatial output into interpretable results, while the instruments segment grows at 22.4%, the slowest of the three, reflecting the capital constraint bearing on instrument purchasing.
Among all the types, the transcriptomics segment is expected to account for the larger share of the spatial genomics and transcriptomics market in 2026, since every commercial platform in current use measures transcripts. The genomics segment is projected to register the faster CAGR of the two segments, growing on demand from cancer research groups investigating genome organization.
Among all the technologies, the imaging based segment is expected to account for the larger share of the spatial genomics and transcriptomics market in 2026. The sequencing based segment is projected to register the highest growth, supported by platforms that reach customers without a capital instrument purchase.
Among all the applications, the oncology segment is expected to account for the largest share of the spatial genomics and transcriptomics market in 2026, supported by the expanding global cancer burden. Other applications, comprising immunology and infectious disease research, are projected to register the fastest growth, while neurology remains weighted toward publicly funded academic research and is therefore more exposed to constrained research appropriation.
Among all the end users, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the spatial genomics and transcriptomics market in 2026, since spend in this segment is committed against program requirements rather than released annually. The contract research organizations segment is projected to register the highest growth, at a CAGR of 27.0%, since outsourcing removes the capital commitment from the institution commissioning the work.
Among all the geographies, North America is projected to account for the largest share of the spatial genomics and transcriptomics market in 2026, supported by the concentration of leading suppliers headquartered in the region, the scale of pharmaceutical research and development activity, and an established academic research base. Asia-Pacific is projected to register the fastest growth during the forecast period of 2026-2036, supported by domestic platform manufacture in China and expanding genomics investment across China, Japan, and India.
The key players operating in the spatial genomics and transcriptomics market are 10x Genomics, Inc. (U.S.), Bruker Corporation (U.S.), Quanterix Corporation (U.S.), Illumina, Inc. (U.S.), Vizgen, Inc. (U.S.), Singular Genomics, Inc. (U.S.), Takara Bio Inc. (Japan), Oxford Nanopore Technologies Plc (U.K.), Revvity, Inc. (U.S.), Resolve Biosciences GmbH (Germany), S2 Genomics, Inc. (U.S.), Cantata Bio (U.S.), and BioSpyder Technologies, Inc. (U.S.).
The spatial genomics and transcriptomics market study presents historical market data value (2024 and 2025), estimated current data (2026), and forecasts for 2036. This market is segmented by offering, type, technology, application, end user, and geography.
Among all the offerings, the consumables segment is expected to account for the largest share of the spatial genomics and transcriptomics market in 2026. The dominant position of this segment is primarily attributed to consumables being proprietary to each platform, with consumption following the utilization of instruments already installed. The software & services segment is projected to register the highest growth, reflecting the analytical capability required to convert spatial output into interpretable results, while the instruments segment grows at 22.4%, the slowest of the three, reflecting the capital constraint bearing on instrument purchasing.
Among all the types, the transcriptomics segment is expected to account for the larger share of the spatial genomics and transcriptomics market in 2026, since every commercial platform in current use measures transcripts. The genomics segment is projected to register the faster CAGR of the two segments, growing on demand from cancer research groups investigating genome organization.
Among all the technologies, the imaging based segment is expected to account for the larger share of the spatial genomics and transcriptomics market in 2026. The sequencing based segment is projected to register the highest growth, supported by platforms that reach customers without a capital instrument purchase.
Among all the applications, the oncology segment is expected to account for the largest share of the spatial genomics and transcriptomics market in 2026, supported by the expanding global cancer burden. Other applications, comprising immunology and infectious disease research, are projected to register the fastest growth, while neurology remains weighted toward publicly funded academic research and is therefore more exposed to constrained research appropriation.
Among all the end users, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the spatial genomics and transcriptomics market in 2026, since spend in this segment is committed against program requirements rather than released annually. The contract research organizations segment is projected to register the highest growth, at a CAGR of 27.0%, since outsourcing removes the capital commitment from the institution commissioning the work.
Among all the geographies, North America is projected to account for the largest share of the spatial genomics and transcriptomics market in 2026, supported by the concentration of leading suppliers headquartered in the region, the scale of pharmaceutical research and development activity, and an established academic research base. Asia-Pacific is projected to register the fastest growth during the forecast period of 2026-2036, supported by domestic platform manufacture in China and expanding genomics investment across China, Japan, and India.
Key Questions Answered in the Report:
- What is the current revenue generated by the spatial genomics and transcriptomics market globally?
- At what rate is the spatial genomics and transcriptomics market demand projected to grow for the next 10 years?
- What are the historical market sizes and growth rates of the spatial genomics and transcriptomics market?
- What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
- Which segments in terms of offering, type, technology, application, and end user are expected to create major traction for the manufacturers in this market?
- What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the manufacturers operating in the spatial genomics and transcriptomics market?
- Who are the major players in the spatial genomics and transcriptomics market? What are their specific product offerings in this market?
- What are the recent strategic developments in the spatial genomics and transcriptomics market? What are the impacts of these strategic developments on the market?
Table of Contents
1 Introduction
2 Research Methodology
4 Market Insights
5 Market Assessment — By Offering
6 Market Assessment — By Type
7 Market Assessment — By Technology
8 Market Assessment — By Application
9 Market Assessment — By End User
10 Market Assessment — By Geography
11 Competition Analysis
12 Company Profiles
13 Appendix
List Of Tables
List Of Figures
Companies Mentioned
- 10x Genomics, Inc.
- Bruker Corporation
- Quanterix Corporation
- Illumina, Inc.
- Vizgen, Inc.
- Singular Genomics, Inc.
- Takara Bio Inc.
- Oxford Nanopore Technologies Plc
- Revvity, Inc.
- Resolve Biosciences GmbH
- S2 Genomics, Inc.
- Cantata Bio
- BioSpyder Technologies, Inc. (U.S.).
